South Korean pharmaceutical company Yuhan (KRX:000100) signed a contract to supply HIV treatment raw material pharmaceutical products (HIV API) to California-based Gilead Sciences.
The contract, valued till December 2026, is valued at 88.8 billion won, Yuhan said in a Thursday regulatory filing with Korea Exchange.
Shares of Yuhan fell nearly 2% in recent trade on Thursday.